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ABSTRACT
Because many patients with unresectable basal cell carcinoma (BCC) are 
aged ≥65 years, this study explores the efficacy and safety of vismodegib in these 
patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC) in 
the ERIVANCE BCC trial and the expanded access study (EAS).We compared patients 
aged ≥65 years to patients aged <65 years taking vismodegib 150 mg/day, using 
descriptive statistics for response and safety. Patients aged ≥65 years (laBCC/mBCC) 
were enrolled in ERIVANCE BCC (33/14) and EAS (27/26). Investigator-assessed 
best overall response rate in patients ≥65 and <65 years was 46.7%/35.7% and 
72.7%/52.6% (laBCC/mBCC), respectively, in ERIVANCE BCC and 45.8%/33.3% and 
46.9%/28.6%, respectively, in EAS. These differences were not clinically meaningful. 
Safety was similar in both groups, although those aged ≥65 years had a higher 
percentage of grade 3-5 adverse events than those aged <65 years. Vismodegib 
demonstrated similar clinical activity and adverse events regardless of age.
INTRODUCTION
Therapeutic options are limited for patients with 
advanced basal cell carcinoma (aBCC), including locally 
advanced (laBCC) or metastatic (mBCC) disease. 
Aberrant activation of the Hedgehog pathway has been 
identified as a key driver in the pathogenesis of BCC, and 
was first described in patients with basal cell carcinoma 
nevus syndrome (BCCNS) [1, 2]. Vismodegib, the first 
Hedgehog pathway inhibitor to be approved by the US 
Food and Drug Administration (FDA), is indicated for 
patients who have aBCC that has recurred after surgery 
or who are not candidates for surgery and radiation 
[3]. In the pivotal aBCC study (ERIVANCE BCC), 
vismodegib demonstrated an objective response rate of 
43% in patients with laBCC and 30% in patients with 
mBCC by independent review [3].
Patients aged ≥65 years have had longer exposure to 
ultraviolet light and may have more difficulty identifying 
new or changing skin lesions because of the presence of 
other age-related changes. For example, patients in this 
age group are more likely than younger patients to have 
declining eyesight or age-related skin changes such as 
actinic lentigo, seborrheic keratosis, or actinic keratosis 
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[4]. Therefore, older patients are more likely to present 
with multiple lesions or with more advanced or neglected 
lesions than younger patients [5, 6]. Furthermore, patients 
aged ≥65 years may be more vulnerable to adverse events 
(AEs) from anticancer treatments because of comorbid 
medical conditions, age-related reductions in organ or 
cognitive function, and reduced physiologic reserves, 
resulting in a shift in the overall benefit-risk ratio of 
treatment [7].
Here, we present the efficacy and safety of 
vismodegib in patients aged ≥65 years with aBCC 
compared with younger patients who were all enrolled 
in the ERIVANCE BCC pivotal trial [3] and the US 
expanded access study (EAS) [8].
RESULTS
Patients
The ERIVANCE BCC trial enrolled 104 patients, 
including 71 (68%) and 33 (32%) with laBCC and with 
mBCC, respectively; 33 (46%) patients with laBCC and 
14 (42%) patients with mBCC were aged ≥65 years. The 
EAS study enrolled 119 patients, of whom 62 (53%) 
and 57 (47%) had laBCC and mBCC, respectively; 27 
(43%) patients with laBCC and 26 (46%) patients with 
mBCC were aged ≥65 years. Apart from age, baseline 
demographic and disease characteristics were generally 
similar between patients aged ≥65 years and those aged 
<65 years (Table 1). Concomitant medical conditions 
(e.g., hypertension, hyperlipidemia) were more frequent 
in patients aged ≥65 years than in younger patients. Basal 
cell carcinoma nevus syndrome, headache, depression, 
insomnia, and seasonal allergies were more common in 
younger patients.
Treatment exposure
Because of early termination of the EAS study, 
the median duration of treatment with vismodegib was 
shorter in the EAS study than in the ERIVANCE BCC 
study. Median treatment durations in patients with 
aBCC aged ≥65 years and <65 years were 9.2 and 10.2 
months in ERIVANCE BCC, respectively, and 5.5 and 
Table 1: Patient demographics and baseline disease characteristics
ERIVANCE BCC (N = 104) EAS (N = 119)
laBCC mBCC laBCC mBCC
≥65 years
(n = 33)
<65 years
(n = 38)
≥65 years
(n = 14)
<65 years
(n = 19)
≥65 years
(n = 27)
<65 years
(n = 35)
≥65 years
(n = 26)
<65 years
(n = 31)
Median age, years 
(range)
75.0 (65–101) 50.5 (21–62) 71.5 (66–92) 53 (38–64) 77 (67–92) 53 (26–63) 71.5 (65–100) 55 (24–63)
Female, n (%) 15 (45.5) 17 (44.7) 4 (28.6) 5 (26.3) 4 (14.8) 15 (42.9) 4 (15.4) 8 (25.8)
White, n (%) 33(100.0) 38 (100.0) 14 (100.0) 19 (100.0) 27 (100.0) 33 (94.3) 25 (96.2) 31 (100.0)
ECOG PS, n (%)
 0 22(66.7) 29 (76.3) 5 (53.7) 8 (42.1) 12 (44.4) 27 (77.1) 14 (53.8) 16 (51.6)
 1 7(21.2) 8 (21.1) 9 (64.3) 10 (52.6) 12 (44.4) 7 (20.0) 10 (38.5) 12 (38.7)
 2 4(12.1) 1 (2.6) 0 1 (5.3) 3 (11.1) 1 (2.9) 2 (7.7) 3 (9.7)
No. of target lesions, n (%)
 1 26(78.8) 22 (57.9) 4 (28.6) 5 (26.3) 16 (59.3) 18 (51.4) 12 (46.2) 12 (38.7)
 2 5 (15.2) 7 (18.4) 2 (14.3) 2 (10.5) 6 (22.2) 7 (20.0) 4 (15.4) 6 (19.4)
 ≥3 2 (6.1) 9 (23.7) 8 (57.2) 12 (63.3) 5 (18.5) 10 (28.5) 10 (38.5) 13 (42.0)
Prior treatment, n (%)
 Surgery 27 (81.8) 35 (92.1) 14 (100.0) 18 (94.7) 25 (92.6) 32 (91.4) 25 (96.2) 29 (93.5)
 Radiotherapy 13 (39.4) 9 (23.7) 9 (64.3) 10 (52.6) 11 (40.7) 9 (25.7) 18 (69.2) 17 (54.8)
 Systemic 
therapy
2 (6.1) 6 (15.8) 2 (14.3) 8 (42.1) 7 (25.9) 4 (11.4) 7 (26.9) 13 (41.9)
Surgery 
contraindicated, 
n (%)
14 (42.4) 29 (76.3) NA NA 18 (66.7) 17 (48.6) NA NA
BCCNS = basal cell carcinoma nevus syndrome; EAS = expanded access study; ECOG PS = Eastern Cooperative 
Oncology Group performance status; laBCC = locally advanced basal cell carcinoma; mBCC = metastatic basal cell 
carcinoma; NA = not applicable.
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5.4 months in the EAS, respectively. Information on 
cumulative exposure to study treatment is presented in 
Table 2.
Best overall response rate
Clinical activity was observed across all cohorts 
in both studies. In the ERIVANCE BCC study, the 
investigator-assessed best overall response rate (BORR) 
was 46.7% (95% confidence interval [CI] 28.3–65.7%) 
and 72.7% (54.5–86.7%) in patients with laBCC aged 
≥65 and <65 years, respectively. In the EAS, the BORR 
was 45.8% (25.6–67.2%) and 46.9% (29.1–65.3%) 
in patients with laBCC aged ≥65 and <65 years, 
respectively. Among patients with mBCC, the BORR 
was 35.7% (95% CI 12.8–64.9%) and 52.6% (95% 
CI 28.9–75.6%) in patients aged ≥65 and <65 years, 
respectively, in the ERIVANCE BCC study, and 33.3% 
(95% CI 13.3–59%) and 28.6% (95% CI 11.3–52.2%) in 
patients aged ≥65 and <65 years, respectively, in the EAS 
(Table 3). Representative examples of individual patient 
responses are shown in Figure 1.
Safety
Within each trial, vismodegib demonstrated a safety 
profile in patients aged ≥65 years similar to that observed 
in younger patients (Table 4). The most frequent AEs in 
patients aged ≥65 vs. <65 years in ERIVANCE BCC and 
the EAS were muscle spasms (64% vs. 72% and 70% vs. 
73%, respectively), dysgeusia (51% vs. 51% and 70% vs. 
73%, respectively), and alopecia (49% vs. 75% and 55% 
vs. 61%, respectively). Grade 3-5 AEs in patients aged 
≥65 vs. <65 years occurred in 51% vs. 35% of patients 
in ERIVANCE BCC and 25% vs. 21% of patients in 
EAS, respectively. Similarly, AEs leading to treatment 
discontinuation occurred in 15% vs. 11% and 11% vs. 2% 
of patients aged ≥65 vs. <65 years in ERIVANCE BCC 
and EAS, respectively. Although numerical differences 
in the incidence of AEs were observed across cohorts, no 
consistent trends were observed across studies. No new 
safety signals were identified.
DISCUSSION
This analysis of the ERIVANCE BCC study 
and the EAS evaluated the efficacy and safety of 
vismodegib in patients with aBCC aged ≥65 years 
compared with those aged <65 years. Vismodegib 
demonstrated similar clinical activity across all patient 
cohorts, including patients aged ≥65 years. Numerical 
differences in response rates between cohorts were not 
considered to be clinically meaningful and were likely 
due to differences in response criteria, assessment 
schedule, treatment duration, and length of follow-up 
in each study.
Patients aged ≥65 years are often considered 
at greater risk of AEs because of the presence of 
comorbidities and age-related impairment of organ 
function [7]. Importantly, the incidence of common 
chronic conditions in these studies (ERIVANCE BCC 
and EAS) was generally similar to that in the general 
population (US Medicare fee-for-service beneficiaries) in 
both patients aged ≥65 years and younger patients, except 
for a lower incidence of diabetes (8–9% and 4–6% in 
Table 2: Exposure to study treatment
ERIVANCE BCC (N = 104) EAS (N = 119)
laBCC mBCC laBCC mBCC
≥65 years
(n = 33)
<65 years
(n = 38)
≥65 years
(n = 14)
<65 years
(n = 19)
≥65 years
(n = 27)
<65 years
(n = 35)
≥65 years
(n = 26)
<65 years
(n = 31)
Median 
total No. 
of 150-mg 
capsules 
taken, n 
(range)
275 
(25–564)
300 
(118–555)
276 
(19–378)
335 
(56–500)
218 
(32–530)
143 
(41–553)
142 
(32–581)
167 
(13–585)
Median 
total 
cumulative 
dose 
(range), g
41  
(4–85)
45  
(18–83)
41  
(3–57)
50  
(8–75)
33  
(5–80)
21  
(6–83)
21  
(5–87)
25  
(2–88)
BCC = basal cell carcinoma; EAS = expanded access study; laBCC = locally advanced basal cell carcinoma; 
mBCC = metastatic basal cell carcinoma; NA = not applicable.
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Table 3: Investigator-assessed best overall response (efficacy-evaluable patients)
ERIVANCE BCC (N = 96) EAS (N = 95)
laBCC mBCC laBCC mBCC
≥65 years
(n = 30)
<65 years
(n = 33)
≥65 years
(n = 14)
<65 years
(n = 19)
≥65 years
(n = 24)
<65 years
(n = 32)
≥65 years
(n = 18)
<65 years
(n = 21)
BORR, n (%) 14 (46.7) 24 (72.7) 5 (35.7) 10 (52.6) 11 (45.8) 15 (46.9) 6 (33.3) 6 (28.6)
[95% CI] [28.3–65.7] [54.5–86.7] [12.8–64.9] [28.9–75.6] [25.6–67.2] [29.1–65.3] [13.3–59] [11.3–52.2]
Complete response 8 (26) 12 (36) 0 0 2 (8) 4 (12) 1 (6) 1 (5)
Partial response 6 (20) 12 (36) 5 (36) 10 (53) 9 (38) 11 (34) 5 (28) 5 (24)
Stable disease 11 (37) 4 (12) 7 (50) 8 (42) 12 (50) 15 (47) 9 (50) 11 (52)
Progressive disease 2 (7) 4 (12) 1 (7) 1 (5) 0 0 1 (6) 2 (10)
Not evaluable/missing 3 (10) 1 (3) 1 (7) 0 1 (4) 2 (6) 2 (11) 2 (10)
BCCNS = basal cell carcinoma nevus syndrome; BORR = best overall response rate; CI = confidence interval; EAS = 
expanded access study; laBCC = locally advanced basal cell carcinoma; mBCC = metastatic basal cell carcinoma.
Figure 1: Representative examples of individual patient responses. Patient 1: Single target lesion in a 59-year-old man at 
screening A. 8 weeks B. 16 weeks C. and 24 weeks D.  (Continued).
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Figure 1: (Continued) Representative examples of individual patient responses. Patient 2: Target lesion on the left temple in 
an 82-year-old man at screening E. 8 weeks F. 16 weeks G. and 24 weeks H.
Table 4: Selected adverse events
Selected AEs, n (%) ERIVANCE BCC (N = 104) EAS (N = 119)
≥65 years
(n = 47)
<65 years
(n = 57)
≥65 years
(n = 53)
<65 years
(n = 66)
Any AE 47 (100) 57 (100) 52 (98) 64 (97)
Grade 3-5 AE 24 (51) 20 (35) 13 (25) 14 (21)
AE leading to 
discontinuation 7 (15) 6 (11) 6 (11) 1 (2)
Muscle spasms 30 (64) 41 (72) 37 (70) 47 (73)
Dysgeusia 24 (51) 29 (51) 37 (70) 47 (73)
Alopecia 23 (49) 43 (75) 29 (55) 40 (61)
Nausea 12 (25) 18 (32) 9 (17) 14 (21)
Diarrhea 8 (17) 15 (26) 14 (26) 16 (24)
Ageusia 7 (15) 5 (9) 2 (4) 1 (2)
Constipation 11 (23) 6 (11) 5 (9) 9 (14)
Arthralgia 6 (13) 10 (18) 0 4 (6)
Decreased weight 23 (49) 25 (44) 10 (19) 9 (14)
Decreased appetite 14 (30) 10 (18) 7 (13) 9 (14)
Fatigue 17 (36) 20 (35) 10 (19) 13 (20)
AE = adverse event; BCCNS = basal cell carcinoma nevus syndrome; EAS = expanded access study.
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patients aged ≥65 and <65 years, respectively, compared 
with a prevalence of 27% and 25%, respectively) [9]. In 
this analysis, the safety profile of vismodegib in patients 
aged ≥65 years appeared to be similar to that observed 
in younger patients. While numerical differences were 
observed between analytical cohorts, no consistent trends 
were observed across the 2 trials. These conditions often 
require treatment with medications known to influence 
hepatic drug metabolism when co-administered with 
inhibitors of drug-metabolizing and transporter enzymes 
[10,11]. However, the therapeutic index of vismodegib 
is broad, with no obvious relationship between exposure 
and AEs. Furthermore, results of clinical studies show 
that various cytochrome (CYP2C8, CYP3A4, CYP2C9) 
substrates and a proton pump inhibitor (rabeprazole) 
do not meaningfully alter the pharmacokinetic profile 
of vismodegib [10,11]. The similar AE profile and the 
tumor response in the <65- and ≥65-year-old patient 
cohorts treated with vismodegib make it reasonable to 
conclude that vismodegib is safe and effective and may 
be concomitantly administered with common medications 
used in patients aged ≥65 years with locally advanced or 
metastatic BCC.
CONCLUSION
The results of this analysis suggest that patients aged 
≥65 years are likely to experience benefit from vismodegib 
similar to that for younger patients without any apparent 
increase in the risk of AEs.
MATERIALS AND METHODS
Study design
ERIVANCE BCC (ClinicalTrials.gov number 
NCT00833417) was an international, multicenter, 
non-comparative phase 2 study. EAS (SHH4811g, 
ClinicalTrials.gov number NCT01160250) was a 
multicenter, open-label, noncomparative expanded access 
study to provide patients with aBCC who lack satisfactory 
treatment options access to vismodegib prior to regulatory 
approval. The EAS was terminated early because of 
FDA approval of vismodegib. All patients signed written 
informed consent before enrolling in either study.
Key eligibility criteria
Key eligibility criteria for the ERIVANCE BCC 
and EAS studies were similar. Patients with mBCC 
were required to have histologic confirmation of distant 
metastasis. Patients with laBCC were required to have 
≥1 lesion measuring ≥10 mm, inoperable or surgery 
contraindicated (e.g., recurrence after ≥2 prior surgeries 
and curative resection deemed unlikely, or anticipated 
substantial morbidity and/or deformity from surgery), 
and prior radiation to ≥1 lesion, unless contraindicated 
or inappropriate. Other criteria included age ≥18 years, 
adequate organ function, and Eastern Cooperative 
Oncology Group performance status ≤2. While the 
ERIVANCE BCC trial required patients to have 
measurable disease according to Response Evaluation 
Criteria in Solid Tumors, version 1.0 (RECIST v1.0) 
guidelines, the EAS study also allowed enrollment of 
patients with nonmeasurable disease. Both trials allowed 
enrollment of patients with BCCNS, as long as all other 
eligibility criteria were met.
Treatment
In both studies, all patients received oral vismodegib 
150 mg/day until disease progression, intolerable toxicity, 
patient withdrawal, or study termination.
Assessments
Efficacy assessments
For mBCC, response was evaluated according to 
RECIST v1.0 in both ERIVANCE BCC and EAS. For 
laBCC, response was assessed according to RECIST v1.0 
in the EAS and to a novel composite endpoint (≥30% 
reduction in externally visible or radiographic dimensions, 
or complete resolution of ulceration if present at baseline) 
in ERIVANCE BCC. Response assessments were 
performed every 8 weeks in ERIVANCE BCC and every 
8–16 weeks in the EAS.
Safety assessments
Adverse events were assessed on a monthly basis 
in both trials and graded according to National Cancer 
Institute Common Terminology Criteria for Adverse 
events (NCI-CTCAE), version 3.0 in the ERIVANCE trial 
and NCI-CTCAE version 4.0 in the EAS trial.
Analysis
All patient data available as of November 26, 2010, 
for ERIVANCE BCC (primary analysis) and April 23, 
2012, for US EAS (final analysis) were included in the 
analyses. Analytic cohorts for patients aged ≥65 and <65 
years were created within each trial for comparison using 
descriptive statistical methods. Data were not pooled 
across the trials because of the described differences in the 
schedule and the criteria for assessment of response. Best 
overall response rate was analyzed in efficacy-evaluable 
patients, and 95% CI was computed using the Clopper-
Pearson method.
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